Hovione Loughbeg supplies medium and large-scale manufacturing active pharmaceutical and drug product intermediates that are approved by European, US and Asian health authorities. Over the last four years, the site has continued to successfully transfer new products, acquire new business, achieve multiple regulatory approvals and attract key talent to the site, which now boasts close to 200 team members.
In May 2018, Hovione concluded the re-instatement of a second active pharmaceutical ingredient building on the site, adding further significant capacity, technical capability and expansion opportunities. This promising expansion creates career development opportunities for existing and new team members.
The site now has all three production buildings in operation for the first time in its history. This major investment in the Loughbeg facility will enable further diversity in the product portfolio and brings major additional capacity to the Hovione group, providing enhanced flexibility and agility to both existing and future customers. “We at Hovione Ireland are looking forward to celebrating our 10th year of operation in 2019,” explains Paul Downing, Hovione Ireland General Manager, “which is also the 60th anniversary of the founding of the company in Portugal.”
In It For Life
“Hovione is a pharmaceutical company dedicated to helping pharmaceutical customers bring new and off-patent drugs to market,” Downing explains. “We do well what is difficult, to give our customers what they cannot find elsewhere.”